New Research Report Just Released:
Top Tips from 42 Years of Investing

Simply sign up for the FREE Cabot Wealth Advisory and we'll immediately give you this latest research report ... absolutely FREE:

Secrets of a Master Trader Exposed

If any occupation requires ongoing learning, it’s investing in the stock market. No one, no matter how good their track record, is perfect at this game. The big difference between run-of-the-mill investors and the great investors is that great investors are always learning and improving.

Following that logic, we’ve been improving and refining our stock picking and market timing systems for 42 years now. During that time, we’ve made a bunch of mistakes; sometimes we’ve repeated those mistakes a few times before correcting the problem. But we’ve always learned from our missteps, and in this report, we want to let you know of a handful of the biggest lessons we’ve learned ... in hopes that you don’t have to learn them the hard way.

The Cabot Wealth Advisory e-letter delivers independent, no-nonsense investment advice, focusing on growth stocks, emerging markets stocks, value stocks and more. You'll learn about hot new stocks and the market timing systems you need to profit from them. We work hard to help you make money! Get it today.

Report image

Enter Email Address:

We Value Your Privacy

Not interested or already a Cabot Wealth Advisory reader?
Click here to never see this message again.

Alexion (ALXN) Drug May Have New Uses

by on September 02, 2011

Alexion Pharmaceuticals (ALXN) expects the Food and Drug Administration to decide if its high-priced Soliris drug can be used to treat additional rare diseases, Investor’s Business Daily reported.

Alexion’s only drug, Soliris, is approved in over 35 countries to treat one rare lift-threatening blood disorder called paroxysmal nocturnal hemoglobinuria or PNH. It costs roughly $400,000 a year to treat a PNH patient with Soliris, reported IBD.

The company may receive approval for the drug’s treatment of atypical Hemolytic Uremic Syndrome, or aHUS, as early as the fourth quarter, and Alexion is working on getting Solaris approved for treating other ultra-rare and severe ailments, including the neuromuscular disease Myasthenia Gravis, according to IBD.

The company is also growing geographically. Between new markets in Asia, Latin America and Eastern Europe, there are 3,000 to 7,000 PNH patients Soliris could address, IBD reported.

Alexion Pharmaceuticals (ALXN) is a Cabot Top Ten Trader stock.

Cabot Wealth Advisory E-letter

Our Free Newsletter

Cabot Wealth Advisory delivers independent, no-nonsense investment advice on how to build long-lasting wealth. Learn about new hot stocks & the market timing indicators to profit from them. Simply enter your email address below - Start today!

We Value Your Privacy